JAGX Jaguar Health Inc
Price (delayed)
$1.11
Market cap
$10.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.24
Enterprise value
$28.36M
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating
Highlights
The equity has soared by 200% YoY and by 41% QoQ
JAGX's quick ratio has surged by 160% year-on-year and by 21% since the previous quarter
Jaguar Health's gross profit has decreased by 11% YoY
JAGX's debt is up by 8% year-on-year and by 2.1% since the previous quarter
Key stats
What are the main financial stats of JAGX
Market
Valuations
Earnings
Shares outstanding
9.24M
Market cap
$10.26M
Enterprise value
$28.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.32
Price to sales (P/S)
0.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.78
Revenue
$10.19M
EBIT
-$34.42M
EBITDA
-$32.03M
Free cash flow
-$29.46M
Per share
Balance sheet
Liquidity
EPS
-$5.24
Free cash flow per share
-$12.54
Book value per share
$3.43
Revenue per share
$4.34
TBVPS
$17.9
Total assets
$61.46M
Total liabilities
$42.4M
Debt
$34.16M
Equity
$16.91M
Working capital
$20.98M
Debt to equity
2.02
Current ratio
2.1
Quick ratio
0.91
Net debt/EBITDA
-0.57
Margins
Efficiency
Dividend
EBITDA margin
-314.5%
Gross margin
79.8%
Net margin
-350.2%
Operating margin
-311.9%
Return on assets
-67%
Return on equity
-405%
Return on invested capital
-79.9%
Return on capital employed
-81.3%
Return on sales
-337.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAGX stock price
How has the Jaguar Health stock price performed over time
Intraday
-7.5%
1 week
-1.77%
1 month
-12.6%
1 year
-93.44%
YTD
-87.78%
QTD
-68.99%
Financial performance
How have Jaguar Health's revenue and profit performed over time
Revenue
$10.19M
Gross profit
$8.13M
Operating income
-$31.77M
Net income
-$35.67M
Gross margin
79.8%
Net margin
-350.2%
The net income has increased by 20% YoY and by 7% QoQ
JAGX's net margin is up by 13% year-on-year and by 7% since the previous quarter
Jaguar Health's gross profit has decreased by 11% YoY
The company's revenue fell by 8% YoY
Growth
What is Jaguar Health's growth rate over time
Valuation
What is Jaguar Health stock price valuation
P/E
N/A
P/B
0.32
P/S
0.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.78
The EPS has soared by 99% YoY and by 88% QoQ
The equity has soared by 200% YoY and by 41% QoQ
The price to book (P/B) is 93% lower than the 5-year quarterly average of 4.9 and 79% lower than the last 4 quarters average of 1.7
The price to sales (P/S) is 95% lower than the 5-year quarterly average of 5.6 and 65% lower than the last 4 quarters average of 0.8
The company's revenue fell by 8% YoY
Efficiency
How efficient is Jaguar Health business performance
The ROE has soared by 64% YoY and by 37% QoQ
The return on invested capital has increased by 42% year-on-year and by 7% since the previous quarter
The company's return on assets rose by 22% YoY and by 11% QoQ
The ROS fell by 12% YoY and by 2.2% QoQ
Dividends
What is JAGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAGX.
Financial health
How did Jaguar Health financials performed over time
JAGX's total assets is 45% greater than its total liabilities
JAGX's quick ratio has surged by 160% year-on-year and by 21% since the previous quarter
Jaguar Health's current ratio has soared by 116% YoY and by 11% from the previous quarter
JAGX's debt is 102% greater than its equity
The equity has soared by 200% YoY and by 41% QoQ
The debt to equity has plunged by 64% YoY and by 28% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.